Role of SIRT1 in Neuropathic Pain from the Viewpoint of Neuroimmunity

2021 ◽  
Vol 27 ◽  
Author(s):  
Youjia Fan ◽  
Rong Dong ◽  
Honghai Zhang ◽  
Buwei Yu ◽  
Han Lu

: The current clinical first-line treatment of neuropathic pain still considers only the nervous system as the target, and its therapeutic effect is limited. An increasing number of studies support the opinion that neuropathic pain is a result of the combined action of the sensory nervous system and the related immune system. Under physiological conditions, both the nervous system and the immune system can maintain homeostasis by adjusting the mitochondrial function when sensing noxious stimulation. However, in the case of neuropathic pain, mitochondrial regulatory dysfunction occurs, which may result from the decreased expression of SIRT1. In this study, we review the role of SIRT1 in neuropathic pain from the viewpoint of neuroimmunity.

2010 ◽  
Vol 1 (4) ◽  
pp. 229-234 ◽  
Author(s):  
Taraneh Moini Zanjani ◽  
Masoumeh Sabetkasaei ◽  
Behnaz Karimian ◽  
Farzaneh Labibi ◽  
Babak Farokhi ◽  
...  

AbstractBackgroundEvidence for a role of immune system in hyperalgesic pain states is increasing. Recent work in neuroimmunology suggests that the immune system does more than simply perform its well known functions of recognizing and removing invading pathogens and tumors. Interest in neuroinflammation and neuroimmune activation has grown rapidly in recent years with the recognition of the role of central nervous system inflammatiom and immune responses in the aetiology of pain states. Among various theories, the role of inflammatory responses of the injured nerve has recently received attention. Cytokines are heterogenous group of polypeptides that activate the immune system and mediate inflammatory responses, acting on a variety of tissue, including the peripheral and central nervous system. Interleukin-6 (IL-6) a pro-inflammatory cytokine, is potentially important in pain aetiology, have pronociceptive actions. Neuropathic pain may be due to a primary insult to the peripheral or central nervous system. Substances released during inflammation from immune cells play an important role in the development and maintenance of chronic pain. Nimesulide, a highly selective cox-2 inhibitor, effectively reduces hyperalgesia due to peripherally administration of inflammatory agents like formalin. The safety of nimesulide was reported for some conditions in which other NSAIDs are contraindicated. Here we have determined the effect of nimesulide on pain behaviour and serum IL-6 level in chronic constriction injury (CCI) model of neuropathic pain.MethodsExperiments were carried out on male Wistar rats, (weight 150–200 g, n = 8). Rats were divided into 3 different groups: 1-CCI + saline 0.9% 2Sham + saline 0.9% (control) 3CCI + drug. Nimesulide (1.25, 2.5, 5 mg/kg, i.p.) was injected 1h before surgery and continued daily to day 14 post-ligation. 42 °C water for thermal hyperalgesia, von Frey filaments for mechanical allodynia, acetone test for cool allodynia and 10 °C water for cold hyperalgesia were respectively used as pain behavioural tests. Behavioural tests were recorded before surgery and on postoperative days 1, 3, 5, 7, 10, 14 and the serum concentration of IL-6 was determined at the day 14.ResultsThe results of this study showed a decrease in hyperalgesia and allodynia following nimesulide administration.ConclusionsIt appears that nimesulide was able to reduce pain behaviour due to nerve inflammation and a parallel decrease in the serum IL-6 concentration was observed.ImplicationsThe immune system is an important mediator in the cascade of events that ultimately results in hyperalgesia. Cytokines contribute to the patheogenesis of neuropathic pain, therefore drugs that inhibit cytokine release from immune cells may reduce inflammatory pain states.


2021 ◽  
Author(s):  
Rongping Liu ◽  
Shasha Du ◽  
Yue Qin ◽  
Wan Zhang ◽  
Xuanzi Li ◽  
...  

Abstract BackgroundBefore the introduction of the chemotherapeutic agent methotrexate, radiotherapy (RT) and steroids have been the sole, first-line treatment of primary central nervous system lymphoma (PCNSL). With the application of methotrexate, the role of RT in the treatment of PCNSL has been challenged. MethodsWe performed observation analysis on 2,486 PCNSL patients between 1988 and 2016 from the Surveillance, Epidemiology and End Results (SEER) database. Propensity score matching (PSM) was employed to ensure well-balanced characteristics of two groups of patients who received RT and those who did not receive it. Two randomized controlled trials (RCTs) were pooled to further evaluate the role of consolidation whole-brain radiotherapy (WBRT) in PCNSL. To clarify whether WBRT is necessary for PCNSL, 27 relapsed patients who attained complete response (CR), partial response (PR) or stable disease (SD) during or after first-line treatment without WBRT for newly diagnosed PCNSL in our institution was retrospectively analyzed; the pattern and location of relapse was identified. ResultsAfter matching, there was no statistical difference on survival between the two groups. In patients did not received chemotherapy, RT significantly improved the survival of patients who undergone biopsy (All P < .0001) or subtotal resection (All P < .0001). In particular, RT helped improve survival for patients with other infectious and parasitic diseases including HIV (OIPDH). Pool-analysis shown the better progression free survival (PFS) of patients with WBRT arm compared with no WBRT arm in per-protocol (PP) population (HR 0.71, 95% CI 0.52 to 0.98). In the 27 relapse patients, 17 (63%) had new measurable enhancing lesions at relapse at a spatially distinct site, the remote recurrence after CR was 9/11 (82%), and after PR was 8/15 (53%). Single lesion occurred remote recurrence was 11/13 (85%), while multiple lesions were 7/14 (50%). We also established a novel prediction model with excellent performance to estimate the potential benefit from RT with respect to the end point of overall survival. ConclusionsRT is still an important method in the treatment of PCNSL, which cannot be removed. More precise studies should be carried out to perfect the treatment strategies of the disease.


2011 ◽  
Vol 71 (10) ◽  
Author(s):  
J Arnold ◽  
ML Barcena de Arellano ◽  
C Rüster ◽  
A Schneider ◽  
S Mechsner

2020 ◽  
Vol 7 (2) ◽  
pp. 205-211
Author(s):  
Kaynat Fatima ◽  
Syed Tasleem Raza ◽  
Ale Eba ◽  
Sanchita Srivastava ◽  
Farzana Mahdi

The function of protein kinases is to transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are linked to the initiation and development of human cancer. The recent development of small molecule kinase inhibitors for the treatment of different types of cancer in clinical therapy has proven successful. Significantly, after the G-protein-coupled receptors, protein kinases are the second most active category of drug targets. Imatinib mesylate was the first tyrosine kinase inhibitor (TKI), approved for chronic myeloid leukemia (CML) treatment. Imatinib induces appropriate responses in ~60% of patients; with ~20% discontinuing therapy due to sensitivity, and ~20% developing drug resistance. The introduction of newer TKIs such as, nilotinib, dasatinib, bosutinib, and ponatinib has provided patients with multiple options. Such agents are more active, have specific profiles of side effects and are more likely to reach the necessary milestones. First-line treatment decisions must be focused on CML risk, patient preferences and comorbidities. Given the excellent result, half of the patients eventually fail to seek first-line treatment (due to discomfort or resistance), with many of them needing a third or even further therapy lines. In the present review, we will address the role of tyrosine kinase inhibitors in therapy for chronic myeloid leukemia.


2020 ◽  
Vol 21 (3) ◽  
pp. 288-301 ◽  
Author(s):  
Lin Zhou ◽  
Luyao Ao ◽  
Yunyi Yan ◽  
Wanting Li ◽  
Anqi Ye ◽  
...  

Background: Some of the current challenges and complications of cancer therapy are chemotherapy- induced peripheral neuropathy (CIPN) and the neuropathic pain that are associated with this condition. Many major chemotherapeutic agents can cause neurotoxicity, significantly modulate the immune system and are always accompanied by various adverse effects. Recent evidence suggests that cross-talk occurs between the nervous system and the immune system during treatment with chemotherapeutic agents; thus, an emerging concept is that neuroinflammation is one of the major mechanisms underlying CIPN, as demonstrated by the upregulation of chemokines. Chemokines were originally identified as regulators of peripheral immune cell trafficking, and chemokines are also expressed on neurons and glial cells in the central nervous system. Objective: In this review, we collected evidence demonstrating that chemokines are potential mediators and contributors to pain signalling in CIPN. The expression of chemokines and their receptors, such as CX3CL1/CX3CR1, CCL2/CCR2, CXCL1/CXCR2, CXCL12/CXCR4 and CCL3/CCR5, is altered in the pathological conditions of CIPN, and chemokine receptor antagonists attenuate neuropathic pain behaviour. Conclusion: By understanding the mechanisms of chemokine-mediated communication, we may reveal chemokine targets that can be used as novel therapeutic strategies for the treatment of CIPN.


2019 ◽  
Vol 20 (1) ◽  
pp. 33-37 ◽  
Author(s):  
Marzia Malcangio

AbstractBackgroundAcute pain is a warning mechanism that exists to prevent tissue damage, however pain can outlast its protective purpose and persist beyond injury, becoming chronic. Chronic Pain is maladaptive and needs addressing as available medicines are only partially effective and cause severe side effects. There are profound differences between acute and chronic pain. Dramatic changes occur in both peripheral and central pathways resulting in the pain system being sensitised, thereby leading to exaggerated responses to noxious stimuli (hyperalgesia) and responses to non-noxious stimuli (allodynia).Critical role for immune system cells in chronic painPreclinical models of neuropathic pain provide evidence for a critical mechanistic role for immune cells in the chronicity of pain. Importantly, human imaging studies are consistent with preclinical findings, with glial activation evident in the brain of patients experiencing chronic pain. Indeed, immune cells are no longer considered to be passive bystanders in the nervous system; a consensus is emerging that, through their communication with neurons, they can both propagate and maintain disease states, including neuropathic pain. The focus of this review is on the plastic changes that occur under neuropathic pain conditions at the site of nerve injury, the dorsal root ganglia (DRG) and the dorsal horn of the spinal cord. At these sites both endothelial damage and increased neuronal activity result in recruitment of monocytes/macrophages (peripherally) and activation of microglia (centrally), which release mediators that lead to sensitisation of neurons thereby enabling positive feedback that sustains chronic pain.Immune system reactions to peripheral nerve injuriesAt the site of peripheral nerve injury following chemotherapy treatment for cancer for example, the occurrence of endothelial activation results in recruitment of CX3C chemokine receptor 1 (CX3CR1)-expressing monocytes/macrophages, which sensitise nociceptive neurons through the release of reactive oxygen species (ROS) that activate transient receptor potential ankyrin 1 (TRPA1) channels to evoke a pain response. In the DRG, neuro-immune cross talk following peripheral nerve injury is accomplished through the release of extracellular vesicles by neurons, which are engulfed by nearby macrophages. These vesicles deliver several determinants including microRNAs (miRs), with the potential to afford long-term alterations in macrophages that impact pain mechanisms. On one hand the delivery of neuron-derived miR-21 to macrophages for example, polarises these cells towards a pro-inflammatory/pro-nociceptive phenotype; on the other hand, silencing miR-21 expression in sensory neurons prevents both development of neuropathic allodynia and recruitment of macrophages in the DRG.Immune system mechanisms in the central nervous systemIn the dorsal horn of the spinal cord, growing evidence over the last two decades has delineated signalling pathways that mediate neuron-microglia communication such as P2X4/BDNF/GABAA, P2X7/Cathepsin S/Fractalkine/CX3CR1, and CSF-1/CSF-1R/DAP12 pathway-dependent mechanisms.Conclusions and implicationsDefinition of the modalities by which neuron and immune cells communicate at different locations of the pain pathway under neuropathic pain states constitutes innovative biology that takes the pain field in a different direction and provides opportunities for novel approaches for the treatment of chronic pain.


2004 ◽  
Vol 3 (4) ◽  
pp. 71-80
Author(s):  
Ya. V. Porovsky ◽  
V. I. Zhankova ◽  
A. I. Ryzhov ◽  
Ye. V. Kalyanov ◽  
F. F. Tetenev

A clinical, electroneuromyographic (ENMG) and pathomorphological investigation of 19 eliminators of accident consequences (EAC) in Chernobyl APP in 1986 and 27 Tomsk region inhabitants living in the accident area that has taken place at radiochemical plant of Siberian Chemical Complex in 1993 has been made with the aim of the influence study of low ionizing radiation levels on the peripheral nervous system. Symptoms of sensory polyneuropathy prevailed in both groups clinically. Mixed affection type has been found at EAC by ENGM method, affection of myelinic nerve fibre membrane has been found at people living in accident trace area. Morphofunctional changes in skin allow considering the role of immune system in mechanisms of neuroglial and neuronal damages, distant by time.


2011 ◽  
Vol 18 (04) ◽  
pp. 562-565
Author(s):  
ABID HUSSAIN ◽  
KISHWAR NAHEED

Objective: To determine the role of chemical syphincterotomy as non surgical management of chronic anal fissure. Study Design: Descriptive. Setting: This study was conducted at Margalla teaching Hospital and United Medical center .Rawalpndi. Period: 1½ years. Patients & Methods: This study included 70 patients of either sex. A personal bio data and detailed history of dietary and bowel habits were registered. Topical 0.2% GTN (Gylciryltrinitrate) was applied to anal verge 2 times per day for the period of two months and its effects were noted. Result: 58 patients (83%) got symptomatic relief and 12 patients (17%) did not get improvement. Conclusions: Chemical syphincterotomy heals majority of the fissure . Topical 0.2% GNT ointment is widely used as a first line treatment in U.K . It is generally accepted as an effective treatment for chronic fissure .


2013 ◽  
Vol 8 (2) ◽  
pp. 64-69
Author(s):  
SS Mahmood ◽  
AKM Abedin ◽  
H Islam ◽  
N Jubaida ◽  
NM Kawsar ◽  
...  

DOI: http://dx.doi.org/10.3329/jafmc.v8i2.16357 JAFMC Vol.8(2) 2012 pp.64-69


Sign in / Sign up

Export Citation Format

Share Document